| 20.32 0.15 (0.74%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.8  |
1-year : | 28.47 |
| Resists | First : | 22.09 |
Second : | 24.37 |
| Pivot price | 19.74 |
|||
| Supports | First : | 18.38 | Second : | 15.3 |
| MAs | MA(5) : | 20.05 |
MA(20) : | 19.77 |
| MA(100) : | 24.73 |
MA(250) : | 24.06 |
|
| MACD | MACD : | -1 |
Signal : | -1.4 |
| %K %D | K(14,3) : | 77.3 |
D(3) : | 72 |
| RSI | RSI(14): 42.5 |
|||
| 52-week | High : | 30.95 | Low : | 18.38 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACAD ] has closed below upper band by 20.5%. Bollinger Bands are 54.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 20.37 - 20.45 | 20.45 - 20.53 |
| Low: | 19.79 - 19.89 | 19.89 - 19.98 |
| Close: | 20.17 - 20.31 | 20.31 - 20.46 |
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Wed, 28 Oct 2026
Acadia Pharmaceuticals Inc. (ACAD) stock price, news, quote and history - Yahoo Finance Australia
Wed, 28 Oct 2026
You can watch Acadia’s UBS conference chat live on Nov. 17. - Stock Titan
Thu, 22 Oct 2026
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Wed, 21 Oct 2026
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026 - Business Wire
Fri, 25 Sep 2026
Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 172 (M) |
| Shares Float | 128 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 100 (%) |
| Shares Short | 8,280 (K) |
| Shares Short P.Month | 9,740 (K) |
| EPS | 2.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.59 |
| Profit Margin | 33.4 % |
| Operating Margin | 12.2 % |
| Return on Assets (ttm) | 3.6 % |
| Return on Equity (ttm) | 35.7 % |
| Qtrly Rev. Growth | 16.3 % |
| Gross Profit (p.s.) | 4.1 |
| Sales Per Share | 6.61 |
| EBITDA (p.s.) | 0.57 |
| Qtrly Earnings Growth | 13.3 % |
| Operating Cash Flow | 160 (M) |
| Levered Free Cash Flow | 69 (M) |
| PE Ratio | 9.11 |
| PEG Ratio | 50.8 |
| Price to Book value | 2.67 |
| Price to Sales | 3.07 |
| Price to Cash Flow | 21.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|